Expert Outlook: Amgen Through The Eyes Of 11 Analysts
Portfolio Pulse from Benzinga Insights
Amgen (NASDAQ:AMGN) has received mixed ratings from 11 analysts, with an average 12-month price target of $291.91, indicating a 5.6% increase from the previous target. Recent actions include ratings adjustments and price target changes by analysts from UBS, Daiwa Capital, BMO Capital, RBC Capital, Truist Securities, Deutsche Bank, and Morgan Stanley. Amgen's financials show a market cap above industry average, a 3.77% revenue growth, a high net margin of 25.06%, an ROE of 23.97%, and an ROA of 1.91%, but a high debt-to-equity ratio of 7.9. The company's portfolio includes drugs like Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, Vectibix, Prolia/Xgeva, Evenity, Repatha, Aimovig, Lumakras, Tezspire, and Kyprolis from the Onyx acquisition. The recent Horizon acquisition adds drugs for rare diseases, including Tepezza.
January 29, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen has a new average 12-month price target of $291.91, reflecting a positive sentiment from analysts. Financials indicate strong market presence and profitability, but with a cautionary high debt-to-equity ratio.
The average price target increase suggests analysts see potential in Amgen's stock, likely due to its strong market cap, revenue growth, and profitability metrics. However, the high debt-to-equity ratio may temper investor enthusiasm, warranting a slightly reduced confidence score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100